The Boston Examiner: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Boston Examiner.

Press releases published on August 4, 2026

Aug. 4, 2026

Peanut Butter Pay is Losing Its Spread — Payscale Finds Employers Plan Higher Pay Increases and More Differentiated Pay Strategies in 2027

Indeterminate GlobeNewswire

Aug. 4, 2026

Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation

Indeterminate GlobeNewswire

Aug. 4, 2026

Wave Life Sciences to Present at Upcoming Investor Conferences

Indeterminate GlobeNewswire

Aug. 4, 2026

Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET

Indeterminate GlobeNewswire

Aug. 4, 2026

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

Indeterminate GlobeNewswire

Aug. 4, 2026

Clinical Nutrition Market to Reach $104.7 Billion by 2031, Driven by Aging Demographics and Rising Chronic Disease Burden

Indeterminate GlobeNewswire

Aug. 4, 2026

ABLi Therapeutics Announces Outcomes from its Parkinson’s-related Biomarker Study Demonstrating Modification of Human Disease with Risvodetinib

Indeterminate GlobeNewswire

Aug. 4, 2026

Cirrus Therapeutics Strengthens Its Position as a Next-Generation Global Ocular Immunology Leader with Singapore Eye Research Institute (SERI) Collaboration and Additional Financing

Indeterminate GlobeNewswire

Aug. 4, 2026

IPG Photonics Announces Second Quarter 2026 Financial Results

Indeterminate GlobeNewswire

Aug. 4, 2026

Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference

Indeterminate GlobeNewswire

Aug. 4, 2026

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Indeterminate GlobeNewswire

Aug. 4, 2026

Oblenio Announces First Patients Dosed in Innovative Phase 1a Trial of LBL-051 in Refractory Autoimmune Diseases

Indeterminate GlobeNewswire

Aug. 4, 2026

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

Indeterminate GlobeNewswire

Aug. 4, 2026

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

Indeterminate GlobeNewswire

Aug. 4, 2026

Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Indeterminate GlobeNewswire

Aug. 4, 2026

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

Indeterminate GlobeNewswire

Aug. 4, 2026

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

Indeterminate GlobeNewswire